JG
LUCD icon

Joel Greenblatt’s Lucid Diagnostics LUCD Stock Holding History

Joel Greenblatt’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,886
Closed -$136K – 1766
2025
Q2 		$136K Buy
14,886
+516
+4% +$666 ﹤0.01% 1604
2025
Q1 		$140K Buy
14,370
+3,927
+38% +$4.71K ﹤0.01% 1490
2024
Q4 		$105K Buy
+10,443
New +$9.21K ﹤0.01% 1403

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Joel Greenblatt's LUCD Position: Q3 2025 in Review

Joel Greenblatt sold out of Lucid Diagnostics (LUCD) in Q3 2025, closing a stake of 14,886 shares — an estimated $136K sold.

Joel Greenblatt first reported a position in LUCD in Q4 2024 and held it in 3 quarters. The position peaked at $140K in Q1 2025. 86 funds tracked by Wall St. Rank hold LUCD as of Q3 2025.

  • Joel Greenblatt reported no remaining Lucid Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Joel Greenblatt sold 14,886 Lucid Diagnostics shares in Q3 2025, an estimated $136K.
  • Joel Greenblatt first reported a position in Lucid Diagnostics in Q4 2024 and held it in 3 quarters.
  • Joel Greenblatt's Lucid Diagnostics position peaked at $140K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2025.

Based on Gotham Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.